MGMT and glioblastoma: This was assessed due to failure to adjust for molecular and genetic testing data in glioblastoma, namely MGMT and IDH mutation status, that have been found to significantly predict outcomes for glioblastoma.26,27 Serious bias was assessed in the classification of interventions domain in the study conducted by Seliger et al.10 due to the patients’ involvement in an ongoing trial.